Table 1 Patient characteristics
From: Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer
Early stage (n = 30) | Advanced stage (n = 64) | |||
|---|---|---|---|---|
Median (range) | Frequency | Median (range) | Frequency | |
Age | 50 (25–73) | 59 (31–88) | ||
Histology | ||||
Serous | 5 | 32 | ||
Mucinous | 13 | 2 | ||
Endometroid | 4 | 14 | ||
Clear cell | 3 | 4 | ||
Adenocarcinoma unspecified | 3 | 12 | ||
Mixed | 2 | 0 | ||
Differentiation | ||||
Low-grade | 16 | 8 | ||
High-grade | 14 | 56 | ||
CA 125 | 24 (0–4325) | 321 (0–44438) | ||
Ascites | ||||
Absent | 23 | 15 | ||
Present | 7 | 49 | ||
FIGO stage | ||||
IIB | 11 | |||
III | 44 | |||
IV | 9 | |||
Cytoreduction (only advanced stage disease) | ||||
Optimal | 35 | |||
Suboptimal | 29 | |||
Progression Free Survival | 116 (0–195) | 17 (0–191) | ||
Overall Survival | 120 (0–195) | 34 (0–191) | ||